Intersect ENT (XENT) Receives a Hold from Canaccord Genuity
In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Hold rating on Intersect ENT (XENT), with a price target of $18.00. The company’s shares closed last Tuesday at $18.74.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 8.8% and a 52.4% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
The word on The Street in general, suggests a Hold analyst consensus rating for Intersect ENT with a $18.17 average price target, a -4.3% downside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.46 and a one-year low of $5.97. Currently, Intersect ENT has an average volume of 400.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.